A new ICER and West Health report finds median drug launch prices climbed to $257,000, the FDA approves GSK’s Hibsago as the first functional-cure therapy for chronic hepatitis B, and CSL names Deborah Waterhouse as CEO and managing director.
|Articles|August 26, 2020
Biovista Uses Artificial Intelligence to Address COVID-19
Author(s)Pharmaceutical Executive Editors
Bioscience firm applies AI and data science to identify existing drugs Atozet and Cablivi as potentially effective therapies for blood clots and inflammation caused by COVID-19.
Advertisement
Two newly repositioned drugs with the potential to combat key symptoms of COVID-19 were announced on Aug. 25 by bioscience firm
This follows a mechanistic rationale Biovista released in March, suggesting Aprotinin and Irbesartan as potential COVID-19 treatments to reduce the effects of the cytokine storm, as well as helping reduce viral loads.
For more information, click
Advertisement
Related to this article
Median Drug Launch Prices Hit $257,000 as Access Barriers Persist, ICER and West Health Report Finds
Median net launch prices for new drugs climbed between 2022 and 2025 to $257,000, according to a new ICER and West Health report that also found persistent coverage and access barriers for patients.
The FDA approved GSK's bepirovirsen for adults with chronic hepatitis B on nucleoside therapy, based on phase 3 trials showing 19% functional cure.
Deborah Waterhouse is leaving ViiV Healthcare to become CEO and managing director of CSL.
Incubate’s John Stanford on why MFN’s first casualty is the moonshot — and why cancer, Alzheimer’s, and rare disease bear the cost.
METiS TechBio and Eli Lilly collaborate on next-generation LNP delivery technology, Incubate’s John Stanford on how MFN deals may shape future pharma decisions, and the FDA grants accelerated approval to GSK’s Jemperli for MSI-H/dMMR locally advanced rectal cancer.
METiS TechBio enters a collaboration with Eli Lilly to develop next-generation, tissue-specific lipid nanoparticle delivery technologies using METiS’s AI-driven lipid discovery platform.
Incubate’s John Stanford on why MFN reduces pharma’s appetite for biotech acquisitions — and why that cedes ground to China.
Advertisement
Advertisement
Trending on PharmExec
1
CSL Names Deborah Waterhouse as CEO and Manager Director
2
The Therapeutic Areas or Deals That Might Be Negatively Impacted by MFN Deals
3
METiS Enters Collaboration with Eli Lilly for Next-Generation Tissue-Specific LNP Delivery Technologies
4
FDA Approves Hibsago (Bepirovirsen) for Chronic Hepatitis B
5